新型MDM2降解剂和p53稳定剂KT-253具有比MDM2小分子抑制剂更高的强度和效率
Yogesh K Chutake1, Michele F Mayo1, Nancy Dumont1
1Kymera Therapeutics, Inc., 500 North Beacon Street, Watertown, Massachusetts.
Molecular cancer therapeutics
|December 9, 2024
概括
一种新的降解剂KT-253,通过克服反循环,有效地准Murine双分钟2 (MDM2). 它在白血病模型中诱导了亡和瘤回归,显示了治疗p53野生类型癌症的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 鼠类双分钟2 (MDM2) 是一种E3结合酶,可以抑制瘤抑制蛋白p53.
- 小分子MDM2/p53相互作用抑制剂的临床活性有限,表明需要改进治疗策略.
- 针对MDM2对于癌症治疗至关重要,特别是在p53野生型恶性瘤中.
研究的目的:
- 评估KT-253,一种新型异构功能降解剂,作为针对MDM2.2的治疗剂的疗效.
- 评估KT-253克服与MDM2抑制相关的抵抗机制的能力.
- 确定KT-253作为单一疗法和与血液和固体瘤的标准治疗相结合的潜力.
主要方法:
- 使用了一种异性生物功能降解剂,KT-253,旨在准MDM2.
- 在各种血液学和固体瘤细胞系中测试了KT-253.
- 在p53野生型急性髓性白血病和急性淋巴细胞白血病异种移植模型中评估KT-253的疗效.
- 评估了KT-253与venetoclax在耐药急性髓性白血病异种移植模型中的联合治疗.
主要成果:
- KT-253证明了MDM2的强大和选择性降解.
- 在临床前白血病模型中,单剂量KT-253诱导了快速亡和持续的瘤回归.
- 在急性髓性白血病模型中,KT-253在组合治疗中使用时克服了venetoclax耐药性.
- 该化合物在一系列血液学和固体瘤系中显示出有效性.
结论:
- KT-253代表了针对MDM2的有前途的治疗策略.
- 药物克服反循环并诱导亡的能力支持其在癌症治疗中的潜力.
- 对于p53野生型的血液和固体恶性瘤,KT-253需要进一步的临床开发,无论是作为单一药物还是组合疗法.
相关概念视频
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K